Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Sagimet Biosciences Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Revenue
2
Research and development
24.9
19.8
38.4
39.1
General and administrative
6.14
13
16
17.8
Operating expenses
31.1
32.7
54.5
56.9
Operating income
-31.1
-30.7
-54.5
-56.9
Other non-operating income
0.56
2.86
8.89
5.85
Income tax
0
0
Net income
-30.5
-27.9
-45.6
-51
EPS, basic
-165.20
-2.66
-1.45
-1.58
EPS, diluted
-165.20
-2.66
-1.45
-1.58
Shares, basic (weighted)
0.18
10.5
31.4
32.3
Shares, diluted (weighted)
0.18
10.5
31.4
32.3
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
0.16
75.1
75.8
35
Short-term investments
32.2
19.8
75.4
78.1
Other current assets
0.03
0.07
0.16
0.2
Total current assets
32.8
96.6
153
116
Lease right-of-use assets
0.21
0.07
0.08
0.08
Long-term investments
7.41
0
Other non-current assets
0
Total assets
33
96.7
160
116
Accounts payable
1.13
0.19
1.43
1.31
Accrued liabilities
4.02
5.4
2.95
3.71
Total current liabilities
5.28
5.65
4.45
5.1
Lease liabilities
0.08
0
Total liabilities
5.36
5.65
4.45
5.1
Paid-in capital
35
341
451
458
Retained earnings
-222
-250
-295
-346
Other comprehensive income
-0.08
0.03
0.23
0.12
Shareholders' equity
-187
91.1
156
111
Total equity
-187
91.1
156
111
Total liabilities and equity
33
96.7
160
116
Shares outstanding
0.19
0
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-30.5
-27.9
-45.6
-51
Stock-based compensation
1.88
4.99
5.29
6.45
Change in payables
2.92
0.12
-0.91
0.93
Cash from operations
-24.5
-23.8
-42.4
-45.7
Purchases of investments
-41.4
-19.6
-108
-107
Sales and maturities of investments
9.44
32.2
46.4
111
Cash from investing
-32
12.6
-61.7
4.56
Stock issued
0.01
0.01
106
0
Cash from financing
-0.07
86.2
105
0.28
Net change in cash
-56.6
75
0.7
-40.8
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.24 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-18.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-17.9%
Net income / average total assets.
Return on invested capital (ROIC)
-46.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-28.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-27.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
52.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
3.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
459.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
45.0x
Current assets / current liabilities.
Quick ratio
44.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
44.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.79
Cash from operations / diluted weighted shares.
Book value per share
$4.82
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
2.22x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.22x
Market cap / tangible book value, when positive.
Earnings yield
-8.3%
Net income / market cap (the inverse of P/E).
Was Sagimet Biosciences Inc. profitable in fiscal 2025?
No. It reported a net loss of $51.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.